Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial |
| |
| Affiliation: | 1. Department of Paediatrics, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;2. Department of Maternal and Children’s Health, Obstetrics and Gynecology Unit, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;3. Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Italy;4. Department of Maternal and Children’s Health, Neonatal Intensive Care Unit, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;1. Environmental and Experimental Pathology, Paulista University (UNIP), Rua Dr. Bacelar 1212, 4th Floor, 04026-002, São Paulo, SP, Brazil;2. Microbiology, Immunology and Parasitology Department, Federal University, Rua Sena Madureira 1500, 04021-001, São Paulo, SP, Brazil;3. Physiopathology Department, Butantan Institute, Rua Vital Brasil 1500, 05503-900, São Paulo, SP, Brazil;1. Department of Microbiology, School of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea;2. Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea;1. Department of Toxicology, School of public health, Zhejiang University School of Medicine, Hangzhou 310058, China;2. Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China;3. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;4. The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 31000, China;5. Department of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou 310000, China;6. Blood center of Zhejiang Province, Hangzhou 310000, China |
| |
| Abstract: | Tumor necrosis factor (TNF) inhibitors have exhibited certain clinical efficacy in treating refractory Takayasu arteritis (TA), albeit with severe adverse effects. We aimed to explore the anti-TNF function of resveratrol, a natural compound, in the treatment of TA. A total of 271 patients diagnosed of acute TA were enrolled in this clinical trial, who were then randomized to be administered 250 mg resveratrol or placebo on a daily basis for a period of 3 months, and revisited biweekly to assess treatment outcomes. Primary treatment outcome was defined as the disease activity, determined using the Birmingham Vascular Activity Score (BVAS). Secondary outcome was defined by laboratory parameters, including erythrocyte sedimentation rate (ESR), plasma levels of C-reactive protein (CRP) and TNF-α. BVAS score and laboratory parameters of patients receiving resveratrol treatment exhibited a steady decline throughout the study. In contrast, outcomes remained practically unchanged in placebo-treated patients. Strong linear correlations were also observed between TNF-α with BVAS scores, ESR and plasma levels of CRP. Resveratrol could greatly improve treatment outcome and laboratory parameters in acute TA patients, likely due to its anti-TNF property. |
| |
| Keywords: | C-reactive protein Resveratrol Erythrocyte sedimentation rate Takayasu arteritis Tumor necrosis factor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
